The carboxylesterase 1 (CES1) antibody is a critical tool for studying the enzyme CES1. a serine hydrolase primarily involved in metabolizing ester-containing drugs, prodrugs, and endogenous lipids. Expressed predominantly in the liver, adipose tissue, and immune cells, CES1 plays a vital role in drug activation (e.g., antiviral agents, antiplatelet drugs) and lipid homeostasis. Dysregulation of CES1 is linked to metabolic disorders, cardiovascular diseases, and neurotoxicity, making it a focus in pharmacology and disease research.
CES1 antibodies are used to detect and quantify CES1 protein levels in various biological samples, aiding in research on tissue-specific expression, enzymatic activity modulation, and disease mechanisms. Monoclonal antibodies offer high specificity for CES1 isoforms, while polyclonal antibodies may detect broader epitopes. Validation via knockout controls or enzymatic assays is essential to ensure antibody reliability.
Recent studies emphasize CES1's role in personalized medicine, particularly in predicting drug metabolism variability due to genetic polymorphisms. Additionally, its involvement in lipid signaling pathways highlights potential therapeutic targets for obesity and diabetes. CES1 antibodies also contribute to diagnostic development, as altered CES1 expression correlates with liver dysfunction and certain cancers. Ongoing research aims to refine antibody specificity and explore CES1's interplay with other metabolic enzymes, advancing its clinical and pharmacological relevance.